🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 78 of 151

  1. Luspatercept

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HSCT

    phase 2 small molecule active

    1 trial

  2. Luspatercept combined with low-dose thalidomide

    The First People's Hospital of Lianyungang

    Transfusion-dependent β-thalassemia Patients

    phase 2 small molecule active

    1 trial

  3. Lusutrombopag Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Idiopathic Thrombocytopenic Purpura

    phase 2 small molecule completed

    1 trial

  4. Lutathera 370 MBq/mL solution for infusion, ATEZOLIZUMAB, Tevimbra 100 mg concentrate for solution for infusion, CARBOPLATIN, LysaKare 25 g/25 g solution for infusion, NETSPOT, ETOPOSIDE

    Novartis Pharmaceuticals

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  5. Lutathera 370 MBq/mL solution for infusion, LysaKare 25 g/25 g solution for infusion

    The George Institute

    Neuroendocrine tumor

    phase 2 small molecule active

    1 trial

  6. Lutetium (177Lu) rhPSMA-10.1 injection

    Blue Earth Diagnostics Ireland Ltd

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  7. Lutikizumab, USP/Ph. Eur.ABBV-323, Universal Placebo (Lutikizumab, Ravagalimab)

    AbbVie Deutschland GmbH & Co. KG

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  8. Luvadaxistat

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  9. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  10. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Lung Cancer

    phase 2 small molecule terminated

    1 trial

  11. Luveris

    Peking University Third Hospital

    Infertility

    phase 2 small molecule active

    1 trial

  12. Luxdegalutamide, DZR123, -, -, DOCETAXEL, CABAZITAXEL, ABIRATERONE, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    Metastatic castrate resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  13. Luxdegalutamide, GOZETOTIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  14. Lynparza 100 mg film-coated tablets, CYCLOPHOSPHAMIDE, Lynparza 150 mg film-coated tablets, DOCETAXEL, DOXORUBICIN, CARBOPLATIN, EPIRUBICIN

    Shanghai Reinovax Biologics Co.,LTD

    Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)

    phase 2 small molecule active

    1 trial

  15. Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Faslodex 250 mg solution for injection., Lynparza 150 mg film-coated tablets, Zoladex 3.6 mg Implant

    Ningbo Cancer Hospital

    ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.

    phase 2 small molecule active

    1 trial

  16. Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    Wuhan Createrna Science and Technology Co., Ltd

    Basket tumors

    phase 2 small molecule active

    1 trial

  17. Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    Fondazione Telethon ETS

    BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer

    phase 2 small molecule active

    1 trial

  18. Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions

    phase 2 small molecule active

    1 trial

  19. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Fondazione Telethon ETS

    recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes

    phase 2 small molecule active

    1 trial

  20. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Verona Pharma Ireland Limited

    Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy

    phase 2 small molecule active

    1 trial

  21. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, ART6043, ART6043, ART6043, ART6043, ART6043

    Lacuna Pharma Pty Ltd

    Metastatic solid tumors, Advanced solid tumors

    phase 2 small molecule active

    1 trial

  22. LysaKare 25 g/25 g solution for infusion, Lutathera 370 MBq/mL solution for infusion

    Advanced Accelerator Applications

    somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas

    phase 2 small molecule active

    1 trial

  23. Lysergide D-tartrate, Placebo for Lysergide tartrate oral solution

    Disc Medicine

    Chronic cluster headache

    phase 2 small molecule active

    1 trial

  24. Lytgobi 4 mg film-coated tablets, 5-FU medac 50 mg/ml, Injektionslösung, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tevimbra 100 mg concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  25. M-CPP

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    2 trials

  26. M1774, M1774, M1774, M1774, M4076, Zejula 100 mg film-coated tablets

    Merck Sharp and Dohme

    Epithelial ovarian cancer that progressed on prior PARP inhibitor therapy

    phase 2 small molecule active

    1 trial

  27. M5049

    Serono Europe Limited

    Coronavirus Disease 2019

    phase 2 small molecule completed

    1 trial

  28. M5049 low dose

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  29. M9140

    Merck Sharp and Dohme

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  30. M9140

    Merck Sharp and Dohme

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  31. M9140

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  32. M9140

    Serono Europe Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  33. MAS825, -

    Novartis Pharmaceuticals

    Still’s disease

    phase 2 small molecule active

    1 trial

  34. MAU868

    Vera Therapeutics

    BK Virus Infection

    phase 2 small molecule completed

    1 trial

  35. MAb-3F8

    United Therapeutics Europe Ltd

    Primary Refractory Neuroblastoma

    phase 2 mab terminated

    1 trial

  36. MB-huCART19.1

    AXIM BIOTECHNOLOGIES, INC.

    B-cell precursor ALL, B-cell Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  37. MB07133

    The First People's Hospital of Lianyungang

    Safety Issues

    phase 2 small molecule active

    1 trial

  38. MB07133 300mg/m2/day

    LIGAND PHARMACEUTICALS INC

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  39. MB07803

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  40. MB07811

    LIGAND PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  41. MBG453, VENETOCLAX, VENETOCLAX, AZACITIDINE, VENETOCLAX

    Novartis Pharmaceuticals

    intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy

    phase 2 small molecule active

    1 trial

  42. MBX 1416 (INN imapextide)

    MBX Biosciences

    Postbariatric Hypoglycemia

    phase 2 small molecule active

    1 trial

  43. MBX 2109

    MBX Biosciences

    Hypoparathyroidism

    phase 2 small molecule completed

    1 trial

  44. MCC-135

    Takeda

    Congestive Heart Failure

    phase 2 small molecule completed

    1 trial

  45. MCLA-128

    Partner Therapeutics Limited

    Solid Tumors

    phase 2 small molecule active

    1 trial

  46. MD-0727

    IRONWOOD PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  47. MD-1100 Acetate

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  48. MD-1100 Acetate

    IRONWOOD PHARMACEUTICALS INC

    Constipation

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.